An observational study of endothelial function in early arthritis

European Journal of Clinical Investigation

Volumn 42, Issue 5, 2012, Pages 510-516

  Foster, Will ^a   Lip, Gregory Y H ^a   Raza, Karim ^b   Carruthers, David ^b   Blann, Andrew D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Circulating endothelial cells; Early arthritis; Endothelium; Vascular endothelial growth factor; Vascular function; Von Willebrand factor

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; METHOTREXATE; STEROID; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTHRITIS; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY ARTHRITIS; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LASER DOPPLER FLOWMETRY; MALE; MICROVASCULAR ENDOTHELIAL CELL; OBSERVATIONAL STUDY; PRIORITY JOURNAL; VASODILATATION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; E-SELECTIN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; STATISTICS AS TOPIC; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84859698912     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02607.x     Document Type: Article

References (29)

1. Belch JJ, Zoma AA, Richards IM, McLaughlin K, Forbes CD, Sturrock RD. Vascular damage and factor-VIII-related antigen in the rheumatic diseases. Rheumatol Int 1987;7:107-11.
2. Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995;34:814-9.
3. Kuuliala A, Eberhardt K, Takala A, Kautiainen H, Repo H, Leirisalo-Repo M. Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study. Ann Rheum Dis 2002;61:242-6.
4. Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol 2007;36:345-50.
5. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
6. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
7. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-205.
8. Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003;48:72-80.
9. Wållberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantapää-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol 2008;37:1-5.
10. Galarraga B, Belch JJ, Pullar T, Ogston S, Khan F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J Rheumatol 2010;37:521-8.
11. Foster W, Carruthers D, Lip GY, Blann AD. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment. J Rheumatol 2010;37:711-6.
12. Foster W, Shantsila E, Carruthers D, Lip GY, Blann AD. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. Rheumatology 2009;48:285-8.
13. Rothschild BM, Masi AT. Pathogenesis of rheumatoid arthritis: a vascular hypothesis. Semin Arthritis Rheum 1982;12:11-31.
14. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002;22:1637-41.
15. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.
16. Klimiuk PA, Sierakowski S, Domyslawska I, Fiedorczyk M, Chwiećko J. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp 2004;52:36-42.
17. Foster W, Carruthers D, Lip GY, Blann AD. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment. J Thromb Thrombolysis 2010;29:437-42.
18. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
19. Machin D, Campbell MJ. Statistical Tables for the Design of Clinical Trials, Chapter 8: Significance of the Correlation Coefficient. Oxford: Blackwell, 1987.
20. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
21. Nadar SK, Lip GY, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005;94:707-12.
22. McClung JA, Naseer N, Saleem M, Rossi GP, Weiss MB, Abraham NG et al. Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA(1)c. Diabetologia 2005;48:345-50.
23. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994;72:979-84.
24. Volin MV. Soluble adhesion molecules in the pathogenesis of rheumatoid arthritis. Curr Pharm Des 2005;11:633-53.
25. Blann AD. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol 1991;50:320-2.
26. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989;53:387-94.
27. Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Ménard JF et al. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007;124:158-64.
28. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
29. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005;105:526-32.